Last reviewed · How we verify
NCT07245940
Assessing Safety of Cervical Spine Fusion With NMP®
trial testing Natural Matrix Protein (NMP) Fibers in Degenerative Disc Disease in 300 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Red Rock Regeneration Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 15 January 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Natural Matrix Protein (NMP) Fibers — full drug profile →
- Cervical interbody fusion
Conditions studied
- Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
- Degenerative Spondylolisthesis — all drugs for Degenerative Spondylolisthesis →
- Spinal Stenosis Cervical — all drugs for Spinal Stenosis Cervical →
Sponsor
Red Rock Regeneration Inc. — full company profile →
Who can join
18 and older, any sex, with Degenerative Disc Disease or Degenerative Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this retrospective chart review study is to assess safety of NMP® in the treatment of cervical spine degenerative conditions by assessing the incidence and nature of AEs in follow-up (minimum of 90 days and up to 2 year post-operatively) as well as reoperation rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07245940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Natural Matrix Protein (NMP) Fibers
Trials testing the same drug.
- NCT06000319 — Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion · enrolling by invitation
Other recruiting trials for Degenerative Disc Disease
Currently open trials in the same condition.
- NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
- NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
- NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting
Other Red Rock Regeneration Inc. trials
Trials by the same sponsor.
- NCT06662266 — Induce XT™ Bone Graft in Foot and Ankle Fusion · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07245940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Red Rock Regeneration Inc.
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07245940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing